List of Excipients in Branded Drug LOSARTAN POTASSIUM TABLETS, 25 MG

« Back to Dashboard

Generic Drugs Containing LOSARTAN POTASSIUM TABLETS, 25 MG

Company	Ingredient	NDC	Excipient
AvKARE	losartan potassium	42291-422	ALUMINUM OXIDE
AvKARE	losartan potassium	42291-422	CELLULOSE, MICROCRYSTALLINE
AvKARE	losartan potassium	42291-422	D&C YELLOW NO. 10
AvKARE	losartan potassium	42291-422	FD&C BLUE NO. 2
AvKARE	losartan potassium	42291-422	INDIGOTINDISULFONATE SODIUM
AvKARE	losartan potassium	42291-422	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in LOSARTAN POTASSIUM TABLETS, 25 MG?

# Of NDCs	Excipient
5	ALUMINUM OXIDE
5	CELLULOSE, MICROCRYSTALLINE
5	D&C YELLOW NO. 10
5	FD&C BLUE NO. 2
5	INDIGOTINDISULFONATE SODIUM
5	LACTOSE MONOHYDRATE

Losartan Potassium Tablets 25 mg: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 25, 2026

Losartan potassium 25 mg tablets are an established, low-cost generic product with no meaningful U.S. compound-patent barrier. Commercial differentiation depends on manufacturing efficiency, low-dose content uniformity, impurity control, patient tolerability, supply reliability and channel access rather than molecular exclusivity. The most attractive opportunities are cost-optimized immediate-release tablets, pediatric or dysphagia-oriented presentations, contract-manufactured private-label products and geographically targeted registrations.

What is the regulatory status of losartan potassium 25 mg tablets?

Losartan potassium tablets are approved in the United States as an immediate-release oral solid dosage form for hypertension, reduction of stroke risk in patients with hypertension and left ventricular hypertrophy, and diabetic nephropathy in patients with type 2 diabetes and hypertension. The reference product is Cozaar, approved under NDA 020386.[1]

Item	Status
Active ingredient	Losartan potassium
Strength	25 mg
Dosage form	Immediate-release tablet
Reference product	Cozaar
Original sponsor	Merck
U.S. regulatory pathway	ANDA generic pathway
Main therapeutic class	Angiotensin II receptor blocker
FDA reference product	NDA 020386
U.S. compound exclusivity	Expired
Current commercial model	Multi-source generic
Typical prescription channels	Retail, mail-order, institutional and government

The 25 mg strength is commercially important because it is used for dose initiation, dose titration, selected elderly patients, patients with hepatic impairment and some pediatric regimens. The standard adult hypertension dose is often 50 mg once daily, but clinicians may initiate therapy at 25 mg in patients receiving diuretics, with volume depletion or with hepatic impairment.[1]

What patents protect losartan potassium tablets?

No active U.S. patent covering the losartan molecule is expected to block generic manufacture or sale of losartan potassium 25 mg tablets. The original losartan patent estate expired years ago, and the product is widely supplied by multiple generic manufacturers.

The relevant patent history includes the original losartan compound patent, U.S. Patent No. 5,138,069, assigned to E.I. du Pont de Nemours and Company. The patent covered substituted imidazole compounds, including losartan, but its term has expired.[2]

Current commercial risk therefore usually arises from:

• Product-specific manufacturing patents.
• Narrow formulation patents.
• Method-of-use patents that may affect label language.
• Process patents covering impurity control or crystallization.
• Regulatory and quality requirements.
• Contracting and supply economics.

A standard losartan potassium 25 mg immediate-release tablet does not generally present the same patent exposure as a new formulation, fixed-dose combination or modified-release product.

What is the Orange Book status of losartan 25 mg?

The FDA Orange Book identifies Cozaar as the reference listed drug for losartan potassium tablets. The product has generic competition across multiple strengths, including 25 mg.[3]

For a conventional losartan potassium tablet:

• An ANDA applicant normally relies on the reference product’s safety and efficacy findings.
• The applicant must demonstrate pharmaceutical equivalence and bioequivalence.
• The applicant must match the reference product’s dosage form, strength, route and labeling, subject to permitted generic labeling differences.
• Paragraph IV litigation is generally not the principal barrier because the core product patents have expired.
• A new patent dispute is more likely to involve a differentiated formulation, delivery system, combination product or process.

The commercial opportunity is therefore a classic mature-generic opportunity rather than an exclusivity-driven launch.

When did losartan lose exclusivity?

Losartan lost effective U.S. small-molecule exclusivity after expiration of the original patent estate and regulatory exclusivity periods. Cozaar was approved in 1995, and generic competition entered the U.S. market in the early 2010s.[1,4]

The key distinction is between regulatory exclusivity and patent protection:

Protection type	Relevance to losartan 25 mg
New chemical entity exclusivity	Expired
Original compound patent	Expired
Standard immediate-release formulation protection	No current blocking barrier generally applicable
Pediatric exclusivity	Expired or no longer commercially relevant to ordinary generic entry
ANDA 180-day exclusivity	Product- and applicant-specific; not a durable market barrier
Current biosimilar exclusivity	Not applicable

Losartan is a chemically synthesized small molecule. Biosimilar rules do not apply.

How should excipients be selected for losartan potassium 25 mg tablets?

The preferred platform is a robust, conventional immediate-release formulation based on direct compression or dry granulation. The 25 mg strength creates a higher content-uniformity challenge than the 50 mg and 100 mg strengths because the active ingredient represents a smaller percentage of total tablet mass.

A typical excipient architecture includes:

Formulation function	Candidate excipients	Commercial rationale
Diluent	Microcrystalline cellulose, lactose monohydrate, dibasic calcium phosphate	Controls tablet weight, flow and compression
Binder	Pregelatinized starch, povidone, hydroxypropyl cellulose	Improves compact strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports immediate release
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force
Film coat	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Provides appearance, protection and identification
Processing aid	Purified water, ethanol or other validated granulation solvent	Used only where required by process

The reference product labeling identifies excipients including microcrystalline cellulose, lactose monohydrate, pregelatinized starch, magnesium stearate and coating materials.[5] Generic products do not need to use the same inactive ingredients unless required for safety, bioequivalence, performance or labeling purposes.

Which excipients best support a low-cost formulation?

Microcrystalline cellulose combined with lactose or pregelatinized starch is a practical first-line platform. It supports:

• High-dose uniformity when the active is geometrically diluted.
• Direct compression or low-complexity granulation.
• Broad supplier availability.
• Acceptable tablet hardness at low compression force.
• Rapid disintegration.
• Straightforward scale-up.

A formulation using direct compression can reduce equipment use, solvent consumption and drying time. Dry granulation may be preferable if the API or blend has poor flow or if wet processing increases impurity risk.

How should the 25 mg strength address content uniformity?

Content uniformity is the central technical issue for the 25 mg presentation. The formulation should use controlled particle-size API, geometric dilution, low-shear blending and validated blend uniformity sampling.

Important process controls include:

1. API particle-size distribution and morphology.
2. Ordered mixing or pre-blending of losartan with a portion of diluent.
3. Controlled lubricant addition time.
4. Segregation control during hopper discharge and tablet compression.
5. Weight control with narrow fill-depth variation.
6. In-process assay or near-infrared monitoring where justified.
7. Unit-dose content uniformity testing under applicable pharmacopeial requirements.

Over-lubrication can slow dissolution and reduce tablet tensile strength. Excessive use of colloidal silicon dioxide can alter flow and compaction. The formulation should be optimized against dissolution, friability, disintegration and assay uniformity rather than tablet hardness alone.

What formulation risks affect losartan potassium tablets?

Losartan products require an impurity-control strategy that covers both the active ingredient and the finished tablet. The risk profile includes degradation during manufacture, storage and distribution, as well as contamination associated with excipients, processing equipment and solvents.

Nitrosamine and azide impurity control

Losartan and other sartans have been subject to regulatory scrutiny for nitrosamine impurities, including NDMA and NDEA, and for azido impurities associated with certain manufacturing routes. FDA has issued guidance and communications requiring risk evaluation, testing and mitigation for nitrosamine contamination.[6]

Excipient strategy should therefore include:

• Supplier qualification for lactose, cellulose, starches and other high-volume excipients.
• Evaluation of nitrite and nitrate contributions.
• Control of amine-containing processing materials where relevant.
• Avoidance of unnecessary nitrosating conditions.
• Stability testing under accelerated and long-term conditions.
• Batch-release testing based on the established control strategy.
• Change-control review when suppliers or grades change.

The excipient itself may not be the source of a sartan impurity, but its impurity profile can affect the overall risk assessment.

Moisture and hydrolytic stability

Moisture can affect powder flow, tablet hardness, disintegration and chemical stability. Hygroscopic excipients should be evaluated against:

• Water activity.
• Packaging moisture transmission.
• Tablet coating performance.
• Long-term assay and dissolution.
• Storage conditions in hot and humid markets.

Alu-Alu blister packaging can provide stronger moisture protection than standard high-density polyethylene bottles but usually carries higher packaging cost. High-density polyethylene bottles with desiccant may offer a better balance for U.S. retail and institutional supply.

Lactose suitability

Lactose is widely used in tablet formulations and appears in reference-product labeling. It lowers cost and supports good compaction. A lactose-free platform may still be commercially useful for selected markets or customer specifications, but removing lactose does not automatically create a regulatory advantage. The substitute must preserve dissolution, manufacturability and stability.

What formulations are protected or commercially differentiated?

The standard 25 mg tablet is difficult to differentiate through conventional excipient substitution because generic applicants must meet pharmaceutical equivalence and bioequivalence requirements. Commercially meaningful opportunities are more likely in delivery and usability.

Potential differentiated platforms include:

Product concept	Commercial opportunity	Regulatory burden
Standard film-coated tablet	Lowest cost and fastest generic replication	ANDA
Uncoated immediate-release tablet	Lower manufacturing cost	ANDA if equivalent
Small swallowable tablet	Elderly and dysphagia positioning	ANDA or supported formulation pathway
Orally disintegrating tablet	Pediatric and swallowing-constrained patients	Often higher development and labeling complexity
Sprinkle or dispersible product	Administration flexibility	May require new comparative performance data
Blister-packed unit dose	Institutional and adherence use	Packaging and stability work
Fixed-dose combination	Hypertension regimen simplification	Product-specific regulatory and patent review
Modified-release product	Potential differentiation	Substantially higher development risk

An orally disintegrating or dispersible losartan product could create a more defensible commercial position than a standard excipient change. The opportunity is limited by the need to establish acceptable taste, mechanical strength, moisture stability, dose uniformity and in-use performance.

What generic entry risks exist for losartan 25 mg?

Generic entry risk is high because the product is mature, widely prescribed and technically straightforward. Price erosion is the primary risk to a new entrant.

The main competitive risks are:

• Multiple approved ANDAs.
• Low-cost API sourcing from established manufacturers.
• Limited physician switching friction.
• Pharmacy benefit manager substitution.
• Tender-driven institutional purchasing.
• Retail generic reimbursement pressure.
• Exposure to wholesaler inventory and return requirements.
• Shorter product life-cycle value for a single-strength launch.

A new entrant can improve economics by launching all three common strengths, 25 mg, 50 mg and 100 mg, on a shared manufacturing platform. A single-strength launch may face unfavorable packaging, validation and sales costs relative to addressable volume.

Which companies compete in losartan potassium tablets?

The U.S. market has historically included products from large generic companies and vertically integrated API-to-finished-dose suppliers. Market participation can change through product discontinuations, acquisitions and supply reallocations.

Relevant competitive groups include:

• Large generic manufacturers with national retail contracts.
• Specialty generic companies focused on cardiovascular products.
• Contract development and manufacturing organizations.
• International suppliers seeking U.S. ANDA commercialization partners.
• Private-label distributors supplying pharmacies and institutions.

The strongest competitive position usually combines approved regulatory files, reliable API supply, multiple strengths, low complaint rates and the ability to maintain supply during API or excipient disruptions.

What licensing and partnering opportunities exist?

Losartan 25 mg offers limited value as a standalone licensed product unless the partner contributes one of four assets:

1. An approved ANDA with commercial history.
2. A low-cost and qualified API source.
3. A differentiated dosage form.
4. Distribution access in an underpenetrated geography.

Potential deal structures include:

• ANDA out-licensing by territory.
• API supply plus finished-dose manufacturing.
• Private-label commercialization.
• Regional registration transfer.
• Hospital and government tender partnerships.
• Portfolio licensing covering losartan, hydrochlorothiazide combinations and other cardiovascular generics.

A package covering losartan 25 mg, 50 mg, 100 mg and losartan/hydrochlorothiazide strengths has greater commercial utility than a single-product license because it supports customer consolidation and shared promotional economics.

How does losartan compare with other generic ARBs?

Drug	Generic maturity	Typical differentiation	Key commercial issue
Losartan	Mature, high competition	Established safety profile, active metabolite, combination products	Strong price pressure
Valsartan	Mature, high volume	Broad cardiovascular use	Supply and impurity history
Irbesartan	Mature	Diabetic nephropathy positioning	Smaller volume in some markets
Telmisartan	Mature	Long half-life and combination products	More complex product positioning
Olmesartan	Mature	Potency and once-daily use	Label and tolerability considerations
Candesartan	Mature	Heart-failure use and clinical familiarity	Higher manufacturing cost in some markets

Losartan retains commercial value because of its long prescribing history, broad generic recognition and availability in multiple strengths. Its disadvantage is limited pricing power.

What manufacturing and geographic opportunities exist?

The most practical manufacturing strategy is a common blend and compression platform for 25 mg, 50 mg and 100 mg tablets. The 25 mg tablet may require a different tablet weight or dilution ratio, but shared excipient grades can reduce inventory complexity.

Geographic opportunities include:

• Emerging markets with expanding hypertension diagnosis.
• Countries with high use of low-cost ARBs.
• Public-sector procurement programs.
• Markets where local production receives registration or tender preference.
• Regions where blister packaging is preferred for distribution stability.
• Private-label supply for pharmacy chains.

The principal manufacturing barriers are not patent-related. They are API qualification, impurity controls, process validation, bioequivalence, stability data, GMP compliance and reliable packaging supply.

What is the revenue opportunity for losartan 25 mg?

Revenue depends on market, channel, reimbursement and contract terms. The 25 mg strength normally represents a smaller unit share than 50 mg, but it has strategic value because it completes the product line and supports titration.

A commercial model should assess:

• Annual tablet demand by strength.
• Net price after wholesaler and payer deductions.
• API cost per tablet.
• Conversion yield and batch size.
• Packaging format.
• Registration cost by country.
• Tender price and minimum-volume commitments.
• Product-return and expiry exposure.
• Working-capital requirements.

The highest-margin opportunity is unlikely to be an unbranded U.S. retail tablet sold solely on price. Better economics may come from regional exclusivity, institutional tenders, private-label supply, combination-product portfolios or differentiated administration formats.

Key Takeaways

• Losartan potassium 25 mg is a mature generic immediate-release product.
• No active U.S. compound patent is expected to block conventional generic entry.
• The principal technical challenge is low-dose content uniformity.
• Microcrystalline cellulose, lactose, pregelatinized starch, a superdisintegrant and magnesium stearate provide a practical baseline platform.
• Nitrosamine, azide impurity, moisture and supplier-change controls are central to product quality.
• A shared 25 mg, 50 mg and 100 mg manufacturing platform improves commercial efficiency.
• Standard tablets face intense price competition and limited differentiation.
• Orally disintegrating, dispersible, sprinkle or unit-dose presentations may create stronger commercial positioning.
• Biosimilar risk is not relevant because losartan is a small-molecule drug.
• Licensing value is strongest when an ANDA, qualified API supply, differentiated formulation or regional distribution channel is included.

FAQs

Is losartan potassium 25 mg still commercially attractive?

Yes, but mainly as part of a broader cardiovascular generic portfolio or a regional/private-label supply strategy. Standalone U.S. commodity pricing is likely to be highly competitive.

Can a company patent a new losartan 25 mg excipient combination?

A conventional excipient substitution is unlikely to provide strong patent protection unless it produces a demonstrable, non-obvious technical effect. A novel delivery system, stability improvement or clinically useful administration format may have stronger patent potential.

Does losartan potassium require a biosimilar application?

No. Losartan is a chemically synthesized small molecule and is regulated through generic drug pathways such as an ANDA, not through the biosimilar pathway.

What packaging is best for losartan 25 mg tablets?

High-density polyethylene bottles with appropriate moisture protection are generally economical for retail distribution. Alu-Alu blisters can be preferable where humidity exposure, unit-dose dispensing or institutional handling justifies the higher cost.

Can losartan 25 mg be developed as an orally disintegrating tablet?

Yes. The product would require formulation development focused on rapid disintegration, taste, mechanical strength, content uniformity, moisture protection and comparative performance. Its regulatory requirements may exceed those of a conventional immediate-release tablet.

References

1. U.S. Food and Drug Administration. (2018). Cozaar (losartan potassium) tablets: Prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Patent and Trademark Office. (1992). U.S. Patent No. 5,138,069: Imidazole-5-acetic acid derivatives. E.I. du Pont de Nemours and Company.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

4. U.S. Food and Drug Administration. (2010). FDA approves first generic versions of Cozaar and Hyzaar. FDA.

5. DailyMed. (2024). Losartan potassium tablets: Inactive ingredients and product labeling. National Library of Medicine.

6. U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry. FDA.